The developer of the Elevate heart pump system, Magenta Medical, recently announced the completion of its FDA-approved Early Feasibility Study for the high-risk percutaneous coronary intervention (HR-PCI) indication.
The first patients treated in the United States with the world’s smallest heart pump are part of an FDA-approved Early Feasibility Study which Magenta Medical has initiated in two leading NY cardiology centers with its Elevate percutaneous Left Ventricular Assist Device (pLVAD) for the high-risk percutaneous coronary intervention (HR-PCI) indication.